• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加强针接种和病毒持续进化在季节性 SARS-CoV-2 循环中的作用。

The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2.

机构信息

Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

出版信息

J R Soc Interface. 2022 Sep;19(194):20220477. doi: 10.1098/rsif.2022.0477. Epub 2022 Sep 7.

DOI:10.1098/rsif.2022.0477
PMID:36067790
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9448498/
Abstract

Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.

摘要

预计未来几年 COVID-19 将周期性复发,而公共卫生干预措施可能能够降低其强度。我们使用传播模型来评估在病原体不断进化的情况下,使用加强针和非药物干预(NPIs)的情况可能会如何影响未来的传播波。我们发现,随着 NPIs 的放松,发病率可能会增加,预计 2022 年秋季将出现第二波季节性驱动的激增。然而,加强针可以大大降低这两波的强度,并在 2022 年 1 月 7 日至 2023 年 1 月 7 日期间减少 20%的累积死亡人数。随着发病率再次开始上升,在秋季重新引入 NPIs 也可能会产生影响。结合加强针和 NPIs 可以使累积死亡人数减少 30%,如果使用针对变异株的加强针,可能会产生更大的影响。在传播率上升的情况下,2022 年秋季重新引入这些 NPIs 可以提供与无限期维持 NPIs 相同的好处(无限期维持 NPIs 和加强针可减少 307000 人死亡,而短暂维持 NPIs 和加强针可减少 304000 人死亡)。如果出现传染性或免疫逃逸增强的新型变体,死亡人数将会更高,但疫苗接种和 NPIs 预计仍然是降低累积和峰值卫生系统负担的有效工具,提供比例相似的相对影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b447/9448498/84eb47701909/rsif20220477f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b447/9448498/1536af890c50/rsif20220477f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b447/9448498/84eb47701909/rsif20220477f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b447/9448498/1536af890c50/rsif20220477f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b447/9448498/84eb47701909/rsif20220477f02.jpg

相似文献

1
The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2.加强针接种和病毒持续进化在季节性 SARS-CoV-2 循环中的作用。
J R Soc Interface. 2022 Sep;19(194):20220477. doi: 10.1098/rsif.2022.0477. Epub 2022 Sep 7.
2
Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.非药物干预措施、疫苗接种和 SARS-CoV-2 德尔塔变异株在英国:一项数学建模研究。
Lancet. 2021 Nov 13;398(10313):1825-1835. doi: 10.1016/S0140-6736(21)02276-5. Epub 2021 Oct 28.
3
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.2021 年秋季德尔塔变异株流行期间英国加强针接种对 COVID-19 的公共卫生影响。
J Med Econ. 2022 Jan-Dec;25(1):1039-1050. doi: 10.1080/13696998.2022.2111935.
4
Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions.预测各州放松非药物干预措施后的 COVID-19 死亡率。
JAMA Health Forum. 2022 Apr 1;3(4):e220760. doi: 10.1001/jamahealthforum.2022.0760. eCollection 2022 Apr.
5
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.2022 年至 2023 年秋冬期间,老年欧洲人群中的 COVID-19 疫苗有效性。
JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.
6
Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.通过非药物干预和为儿童接种疫苗来减轻澳大利亚的 SARS-CoV-2 Delta 疾病负担:建模分析。
BMC Med. 2022 Feb 18;20(1):80. doi: 10.1186/s12916-022-02241-3.
7
COVID-19 outbreaks in residential aged care facilities: an agent-based modeling study.基于代理的建模研究:老年人护理设施中的 COVID-19 疫情爆发。
Front Public Health. 2024 May 21;12:1344916. doi: 10.3389/fpubh.2024.1344916. eCollection 2024.
8
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.SARS-CoV-2 感染和≥18 岁成年人住院情况,按疫苗接种状态,在 SARS-CoV-2 B.1.1.529(奥密克戎)变异株流行之前和期间——加利福尼亚州洛杉矶县,2021 年 11 月 7 日-2022 年 1 月 8 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):177-181. doi: 10.15585/mmwr.mm7105e1.
9
Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories.厘清非药物干预措施和疫苗接种对欧洲 COVID-19 传播轨迹的变化影响。
Nat Commun. 2022 Jun 3;13(1):3106. doi: 10.1038/s41467-022-30897-1.
10
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland.接种疫苗和非药物干预措施对瑞士 SARS-CoV-2 动力学的影响。
Epidemics. 2022 Mar;38:100535. doi: 10.1016/j.epidem.2021.100535. Epub 2021 Dec 14.

引用本文的文献

1
Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.评估美国向年度 SARS-CoV-2 疫苗接种活动过渡的策略。
Ann Intern Med. 2024 May;177(5):609-617. doi: 10.7326/M23-2451. Epub 2024 Mar 26.
2
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.一种靶向T细胞的多抗原疫苗可产生针对新冠病毒感染的强大细胞免疫和体液免疫。
Mol Ther Methods Clin Dev. 2023 Sep 16;31:101110. doi: 10.1016/j.omtm.2023.101110. eCollection 2023 Dec 14.
3
Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget.

本文引用的文献

1
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.南加州与 SARS-CoV-2 奥密克戎(B.1.1.529)变异株以及 BA.1/BA.1.1 或 BA.2 亚变异株感染相关的临床结局。
Nat Med. 2022 Sep;28(9):1933-1943. doi: 10.1038/s41591-022-01887-z. Epub 2022 Jun 8.
2
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease.2019冠状病毒病疫苗对严重急性呼吸综合征冠状病毒2感染及疾病的有效性和效果的系统评价
Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138. doi: 10.1093/ofid/ofac138. eCollection 2022 Jun.
3
确定一种最佳的新冠病毒加强针分配策略,以便在固定医疗预算下使医院病床使用天数最少。
Vaccines (Basel). 2023 Feb 7;11(2):377. doi: 10.3390/vaccines11020377.
4
Designing the Safe Reopening of US Towns Through High-Resolution Agent-Based Modeling.通过基于智能体的高分辨率建模设计美国城镇的安全重新开放。
Adv Theory Simul. 2021 Sep;4(9):2100157. doi: 10.1002/adts.202100157. Epub 2021 Aug 1.
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
4
Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.当前关于 COVID-19 加强针疫苗接种对奥密克戎变异株有效性的证据:系统评价。
J Med Virol. 2022 Jul;94(7):2969-2976. doi: 10.1002/jmv.27697. Epub 2022 Mar 14.
5
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel.接种 BNT162b2 可降低以色列家庭接触者中 SARS-CoV-2 的传播。
Science. 2022 Mar 11;375(6585):1151-1154. doi: 10.1126/science.abl4292. Epub 2022 Jan 27.
6
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
7
Omicron variant and booster COVID-19 vaccines.奥密克戎变种与新冠病毒加强疫苗
Lancet Respir Med. 2022 Feb;10(2):e17. doi: 10.1016/S2213-2600(21)00559-2. Epub 2021 Dec 17.
8
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.与关注的阿尔法(B.1.1.7)变体相比,感染新冠病毒德尔塔(B.1.617.2)变体的住院和急诊就诊风险:一项队列研究。
Lancet Infect Dis. 2022 Jan;22(1):35-42. doi: 10.1016/S1473-3099(21)00475-8. Epub 2021 Aug 27.
9
SARS-CoV-2 variants, spike mutations and immune escape.SARS-CoV-2 变体、刺突突变和免疫逃逸。
Nat Rev Microbiol. 2021 Jul;19(7):409-424. doi: 10.1038/s41579-021-00573-0. Epub 2021 Jun 1.
10
Projecting social contact matrices in 152 countries using contact surveys and demographic data.利用接触调查和人口数据预测152个国家的社会接触矩阵。
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697. doi: 10.1371/journal.pcbi.1005697. eCollection 2017 Sep.